For research use only. Not for therapeutic Use.
Luvadaxistat (TAK-831) is an orally active, highly selective, potent D-amino acid oxidase (DAAO) inhibitor. Luvadaxistat inhibits oxidative deamination of D-serine via the human recombinant DAAO enzyme with an IC50 of 14 nM. Luvadaxistat significantly increases D-serine levels in the rodent brain, plasma, and cerebrospinal fluid. Luvadaxistat has the potential for schizophrenia research[1][2].
Luvadaxistat (TAK-831; 0.001-3 mg/kg/days; PO; 14 days) dose-dependently improves social behavior in the social interaction (SI) test in BALB/c animals with rodent models of negative symptoms of schizophrenia[1].
Acute dosing of Luvadaxistat (0.3, 1, 3 mg/kg; p.o.) significantly reverses a poly(I:C)-induced deficit social preference in male C57BL/6 poly(I:C)-treated mice[1].
Luvadaxistat (1, 3, 10 mg/kg; p.o. at 2, 6, 10, and 24 h) inhibits DAAO by increased rat cerebellar d-serine levels in a dose- and time-dependent manner with a maximal effect observed at a dose of 10 mg/kg at 10 h post-dose in male Wistar rats weighing 240-280 g[1].
| Catalog Number | I031181 |
| CAS Number | 1425511-32-5 |
| Synonyms | 6-[2-[4-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione |
| Molecular Formula | C13H11F3N2O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C13H11F3N2O2/c14-13(15,16)9-4-1-8(2-5-9)3-6-10-7-11(19)12(20)18-17-10/h1-2,4-5,7H,3,6H2,(H,17,19)(H,18,20) |
| InChIKey | QBQMUMMSYHUDFM-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1CCC2=CC(=O)C(=O)NN2)C(F)(F)F |
| Reference | [1]. Rosa Fradley, et al. Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia. [2]. Wang H, Norton J, Xu L, DeMartinis N, Sen R, Shah A, Farmer J, Lynch D. Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxia. Ann Clin Transl Neurol. 2021 Jun;8(6):1343-1352. |
